Cargando…
Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients
Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make patients more susceptible to viral, bacterial, and fungal infections because of their mechanism of action. They not only increase the risk of new infections but also act altering the natural course of preexisting infe...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623386/ https://www.ncbi.nlm.nih.gov/pubmed/23606869 http://dx.doi.org/10.1155/2013/410521 |
_version_ | 1782265913729351680 |
---|---|
author | Laurenti, R. Giovannangeli, F. Gubinelli, E. Viviano, M. T. Errico, A. Leoni, L. Ballanti, E. Migliore, A. |
author_facet | Laurenti, R. Giovannangeli, F. Gubinelli, E. Viviano, M. T. Errico, A. Leoni, L. Ballanti, E. Migliore, A. |
author_sort | Laurenti, R. |
collection | PubMed |
description | Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make patients more susceptible to viral, bacterial, and fungal infections because of their mechanism of action. They not only increase the risk of new infections but also act altering the natural course of preexisting infections. While numerous data regarding the reactivation of tuberculosis infection are available in the literature, poor information about the risk of reactivation or exacerbation of hepatitis viruses B and C infections during treatment with biologics has been reported. Furthermore, reported series with biological therapy included short periods of followup, and therefore, they are not adequate to verify the risk of reactivation in the long-term treatment. Our study evaluated patients with a history of hepatitis B and psoriatic arthritis treated with adalimumab and monitored up to six years. During the observation period, treatment was effective and well tolerated in all patients, and liver function tests and viral load levels remained unchanged. |
format | Online Article Text |
id | pubmed-3623386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-36233862013-04-19 Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients Laurenti, R. Giovannangeli, F. Gubinelli, E. Viviano, M. T. Errico, A. Leoni, L. Ballanti, E. Migliore, A. Clin Dev Immunol Clinical Study Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make patients more susceptible to viral, bacterial, and fungal infections because of their mechanism of action. They not only increase the risk of new infections but also act altering the natural course of preexisting infections. While numerous data regarding the reactivation of tuberculosis infection are available in the literature, poor information about the risk of reactivation or exacerbation of hepatitis viruses B and C infections during treatment with biologics has been reported. Furthermore, reported series with biological therapy included short periods of followup, and therefore, they are not adequate to verify the risk of reactivation in the long-term treatment. Our study evaluated patients with a history of hepatitis B and psoriatic arthritis treated with adalimumab and monitored up to six years. During the observation period, treatment was effective and well tolerated in all patients, and liver function tests and viral load levels remained unchanged. Hindawi Publishing Corporation 2013 2013-03-27 /pmc/articles/PMC3623386/ /pubmed/23606869 http://dx.doi.org/10.1155/2013/410521 Text en Copyright © 2013 R. Laurenti et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Laurenti, R. Giovannangeli, F. Gubinelli, E. Viviano, M. T. Errico, A. Leoni, L. Ballanti, E. Migliore, A. Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients |
title | Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients |
title_full | Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients |
title_fullStr | Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients |
title_full_unstemmed | Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients |
title_short | Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients |
title_sort | long-term safety of anti-tnf adalimumab in hbc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623386/ https://www.ncbi.nlm.nih.gov/pubmed/23606869 http://dx.doi.org/10.1155/2013/410521 |
work_keys_str_mv | AT laurentir longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients AT giovannangelif longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients AT gubinellie longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients AT vivianomt longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients AT erricoa longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients AT leonil longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients AT ballantie longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients AT migliorea longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients |